Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 26, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia
View HTML
Toggle Summary Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
— Visirna Therapeutics, the Joint Venture formed by Arrowhead and Vivo , received an exclusive license in Greater China to four of Arrowhead’s RNAi-based investigational cardiometabolic medicines — Vivo provided an initial investment of $60 million into Visirna — Arrowhead and Vivo both received
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 20, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 second quarter ended March 31, 2022 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 6, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 1, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 23
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 1, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 31 st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) – March 30-April 3, 2022
View HTML
Toggle Summary Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
- Company to Host Pulmonary R&D Day on May 26, 2022 PASADENA, Calif. --(BUSINESS WIRE)--Mar. 24, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MUC5AC, the company’s investigational
View HTML
Toggle Summary Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 15, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce
View HTML
Toggle Summary Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
- Topline data expected in the first half of 2023 PASADENA, Calif. --(BUSINESS WIRE)--Feb. 24, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES -2 clinical study of ARO-ANG3, the
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 18, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 17, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML